Stockreport

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

Cadrenal Therapeutics, Inc.  (CVKD) 
PDF Encouraging data for CAD-1005 in Phase 2 HIT Study  EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition [Read more]